The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

People living with atopic dermatitis (AD, also known as eczema) are also at significantly higher risk for peripheral vascular disease ... of dementia and Parkinson's disease, according to a ...

The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat movement-related symptoms of Parkinson's disease, the drugmaker said on Tuesday.

The lack of proper blood flow deprives brain cells of oxygen and nutrients, leading to damage or death of brain tissue.

Dancing the Blues Away' Seen in Brain Imaging in People With Parkinson's Disease, New Study Finds Dec. 18, 2024 — Dancing lowers the depression associated with Parkinson's disease, and the ...

The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.In a press release, Supernus ...

A 3D model accurately mimicking the blood-brain barrier (BBB) in a laboratory environment has been successfully developed by ...